XNAS
TELA
Market cap47mUSD
Oct 08, Last price
1.05USD
1D
-1.87%
1Q
23.97%
IPO
-91.83%
Name
TELA Bio Inc
Chart & performance
P/E
—
P/S
0.59
EPS
—
Div yield, %
—
Shrs. gr., 5y
29.41%
Rev. gr., 5y
34.54%
Revenues
80m
+15.84%
Net income
-39m
L+2.62%
CFO
-28m
L-32.16%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Key people
Douglas Evans
Independent Chairman of the Board · since 2020
Jeffrey Blizard
President · since 2025
Antony Koblish
President, Chief Executive Officer, Co-Founder, Director · since 2016
Roberto Cuca
Chief Financial Officer, Chief Operating Officer · since 2023
Paul Talmo
Chief Technology Officer · since 2023
Greg Firestone
Chief Commercial Officer · since 2024
Kurt Azarbarzin
Independent Director · since 2020
Vince Burgess
Independent Director · since 2014
Federica O'Brien
Independent Director · since 2019
William Plovanic
Independent Director · since 2025
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||